Liquid formulations of indacaterol
Aqueous formulations of indacaterol are disclosed. The formulations may find use in the treatment of respiratory disorders, inflammatory disorders, or obstructive airway diseases. Methods of using the formulations and kits comprising the formulations are also encompassed by the disclosure.
1. A method of treating a respiratory disorder, an inflammatory disorder of the airways and/or lungs, or an obstructive airway disease, the method comprising:
delivering an aqueous pharmaceutical composition to the lungs of a patient in need thereof, wherein:
the aqueous pharmaceutical composition comprises:
from about 20 weight percent to about 99.9 weight percent water;
indacaterol present at a concentration of about 10 μg/mL to about 600 μg/mL;
glycopyrrolate, or a pharmaceutically acceptable salt thereof, present at a concentration of about 10 μg/mL to about 600 μg/mL;
two or more tonicity modifiers; and
a buffer, wherein
the indacaterol is present as a free base or as a pharmaceutical acceptable salt thereof without the presence of maleic acid from a maleate salt in the aqueous pharmaceutical composition,
one of the two or more tonicity modifiers is present at a concentration from about 100 mM to about 500 mM, and
the aqueous pharmaceutical composition is buffered to a pH from 2 to 6.
2. The method of claim 1 , wherein the respiratory disorder, inflammatory disorder of the airways and/or lungs, or obstructive airway disease is chronic obstructive pulmonary disease (COPD).
3. A method of preparing the aqueous pharmaceutical composition of claim 1 , the method comprising steps a) and b):
a) adding the indacaterol and the glycopyrrolate, or a pharmaceutically acceptable salt thereof, to a liquid comprising water to form a mixture; and
b) adjusting a pH of the mixture to obtain the aqueous pharmaceutical composition.
4. The method of claim 3 , wherein step b) comprises adding an acid or an acid form of the buffer, wherein the acid or the acid form of the buffer is added until the water has a pH equal to or below 2.0.
5. The method of claim 1 , wherein the respiratory disorder, the inflammatory disorder of the airways and/or lungs, or the obstructive airway disease is asthma.
6. The method of claim 1 , wherein the aqueous pharmaceutical composition is administered to the lungs of the patient in need thereof at least once daily.
7. The method of claim 6 , wherein the aqueous pharmaceutical composition is administered to the lungs of the patient in need thereof twice daily.
8. The method of claim 1 , wherein the indacaterol is present at a concentration of about 50 μg/mL to about 200 μg/mL in the aqueous pharmaceutical composition.
9. The method of claim 1 , wherein the water is present in an amount ranging from about 80 weight percent to about 99.9 weight percent in the aqueous pharmaceutical composition.
10. The method of claim 1 , wherein the buffer comprises an anion selected from the group consisting of acetate, bromide, chloride, citrate, furoate, fumarate, propionate, succinate, sulfate, tartrate, and xinafoate.
11. The method of claim 10 , wherein the anion of the buffer in the aqueous pharmaceutical composition is acetate.
12. The method of claim 11 , wherein the buffer in the aqueous pharmaceutical composition is prepared from a combination of acetic acid and sodium hydroxide.
13. The method of claim 11 , wherein the buffer in the aqueous pharmaceutical composition is prepared from a combination of acetic acid and sodium acetate.
14. The method of claim 10 , wherein the anion of the buffer in the aqueous pharmaceutical composition is citrate.
15. The method of claim 14 , wherein the buffer in the aqueous pharmaceutical composition is prepared from a combination of citric acid and trisodium citrate.
16. The method of claim 14 , wherein the buffer in the aqueous pharmaceutical composition is prepared from a combination of citric acid and sodium hydroxide.
17. The method of claim 10 , wherein the anion of the buffer in the aqueous pharmaceutical composition is tartrate.
18. The method of claim 1 , wherein the aqueous pharmaceutical composition comprises a pH from 2 to 5.
19. The method of claim 1 , wherein the aqueous pharmaceutical composition comprises a pH from 3 to 5.
20. The method of claim 1 , wherein aqueous pharmaceutical composition further comprises tiotropium bromide.
21. The method of claim 1 , wherein the glycopyrrolate, or a pharmaceutically acceptable salt thereof, is glycopyrronium bromide.
22. The method of claim 1 , wherein the glycopyrrolate, or a pharmaceutically acceptable salt thereof, is present in the aqueous pharmaceutical composition at a concentration in a range from about 50 μg/mL to about 200 μg/mL.
23. The method of claim 1 , wherein:
the concentration of the indacaterol in the aqueous pharmaceutical composition is between about 50 μg/mL to about 200 μg/mL; and
the concentration of the glycopyrrolate, or a pharmaceutically acceptable salt thereof, in the aqueous pharmaceutical composition is between about 50 μg/mL to about 200 μg/mL.
24. The method of claim 1 , wherein the concentration of the indacaterol is greater than the concentration of the glycopyrrolate, or a pharmaceutically acceptable salt thereof, in the aqueous pharmaceutical composition.
25. The method of claim 1 , wherein the aqueous pharmaceutical composition further comprises mometasone, or a pharmaceutically acceptable salt thereof.
26. The method of claim 1 , wherein:
the indacaterol is present in the aqueous pharmaceutical composition at a concentration of about 50 μg/mL to about 200 μg/mL; and
the aqueous pharmaceutical composition is buffered to a pH from 2 to 5.
27. The method of claim 1 , wherein:
the water is present in the aqueous pharmaceutical composition in an amount ranging from about 80 weight percent to about 99.9 weight percent;
the indacaterol is present in the aqueous pharmaceutical composition at a concentration of about 50 μg/mL to about 200 μg/mL; and
the glycopyrrolate, or a pharmaceutically acceptable salt thereof, is present in the aqueous pharmaceutical composition at a concentration of about 50 μg/mL to about 200 μg/mL.
28. The method of claim 1 , wherein the aqueous pharmaceutical composition is suitable for delivery to lungs of a patient in need thereof using a device.
29. The method of claim 28 , further comprising administering an inhaled corticosteroid to the lungs of the patient in need thereof using the device.
30. The method of claim 3 , wherein step b) comprises waiting for a time period until the mixture reaches an equilibrium.
31. The method of claim 30 , wherein the time period is between about 12 hours to about 72 hours.
32. The method of claim 4 , wherein the buffer comprises an anion selected from the group consisting of acetate, bromide, chloride, citrate, furoate, fumarate, propionate, succinate, sulfate, tartrate, and xinafoate.
33. The method of claim 32 , wherein the anion of the buffer is selected from the group consisting of acetate, citrate, and tartrate.
34. A device for delivering the aqueous pharmaceutical composition of claim 1 and an inhaled corticosteroid to lungs of a patient in need thereof.
35. The method of claim 1 , wherein the method further comprises aerosolizing the aqueous pharmaceutical composition via a jet nebulizer.
36. The method of claim 1 , wherein the method further comprises aerosolizing the aqueous pharmaceutical composition via a vibrating mesh nebulizer.
37. The method of claim 1 , wherein the one of the two or more tonicity modifiers is present at a concentration from about 100 mM to about 200 mM.
38. The method of claim 1 , wherein the two or more tonicity modifiers comprises sodium chloride.
39. The method of claim 38 , wherein sodium chloride is present at about 10 mM.